ABO不同型血浆输注的风险认知与临床实践进展

doi:10.3969/j.issn.1671-2587.2024.02.003

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (2): 164-172.DOI: 10.3969/j.issn.1671-2587.2024.02.003

ABO不同型血浆输注的风险认知与临床实践进展

张雷英, 于洋

解放军总医院第一医学中心输血医学科,北京 100853

收稿日期:2024-02-04 出版日期:2024-04-20 发布日期:2024-04-23
通讯作者: 于洋,主要从事输血免疫和野战输血研究,（E-mail）yuyangpla301@163.com。
作者简介:张雷英,主要从事输血治疗和患者血液管理研究,（E-mail）zhangleiying0312@163.com。

Risks of ABO Non-identical Plasma:Cognitive and Clinical Practice

ZHANG Leiying, YU Yang

Department of Transfusion Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853

Received:2024-02-04 Online:2024-04-20 Published:2024-04-23

摘要/Abstract

摘要： 血浆输注可补充各类凝血因子、纠正凝血功能障碍,在大出血患者的救治中发挥着重要作用。通用型血浆和低效价O型全血能够提高大出血患者紧急输血的时效性和血液成分的可及性,ABO不同型血浆输注策略逐渐在国外临床实践中得到推广和应用。ABO不同型血浆输注分为主动输注和被动输注,主动输注的血浆主要包括AB型血浆和A型血浆;被动输注是以低效价O型全血和不同型单采血小板的形式输注不同型血浆,这些ABO不同型血浆输注会存在一定程度的溶血风险和循环免疫复合物风险。因此,理解ABO不同型血浆输注产生的风险,权衡急救输血过程中ABO不同型血浆输注策略带来的收益,是一个值得关注并深入探讨的问题。

关键词: ABO不同型, ABO不相容, 血浆, 全血, 血小板, 风险

Abstract: Plasma transfusion is clinically used to replenish clotting factors and correct coagulopathy, playing an important role in the treatment of massive hemorrhage. Universal plasma and low titer group O whole blood can improve the timeliness and accessibility of urgent transfusions in patients with major bleeding. The strategy of ABO non-identical plasma transfusion, in the form of active and passive transfusion, has been extensively adopted in clinical practice. Active transfusion mainly includes group AB and A plasma; passive transfusion, on the other hand, involves the transfusion of low titer group O whole blood and ABO non-identical platelets. However, hemolysis and circulating immune complex formation are recognized to be the risks associated with transfusion of ABO non-identical plasma. Together, the risk-benefit trade-off with transfusion of non-ABO identical plasma deserves more attention and further exploration.

Key words: ABO non-identical, ABO-Incompatible, Plasma, Whole blood, Platelet, Risk

中图分类号:

R457

张雷英, 于洋. ABO不同型血浆输注的风险认知与临床实践进展[J]. 临床输血与检验, 2024, 26(2): 164-172.

ZHANG Leiying, YU Yang. Risks of ABO Non-identical Plasma:Cognitive and Clinical Practice[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 164-172.

参考文献

[1] HOLCOMB J B,DEL JUNCO D J,FOX E E,et al.The prospective,observational,multicenter,major trauma transfusion (PROMMTT) study:comparative effectiveness of a time-varying treatment with competing risks[J].JAMA Surg,2013,148(2):127-136.
[2] 中华人民共和国卫生部.临床输血技术规范[S].2000.
[3] 国家卫生健康委员会.全血和成分血使用[S].2018.
[4] Claudia S.Cohn.AABB technical manual(20th edition)[M].Bethesda,MD:AABB Press, 2020.
[5] STANWORTH S J,DOWLING K,CURRY N,et al.Haematological management of major haemorrhage:a British Society for Haematology Guideline[J].Br J Haematol,2022,198(4):654-667.
[6] ZIELINSKI M D,SCHRAGER J J,JOHNSON P,et al.Multicenter comparison of emergency release group A versus AB plasma in blunt-injured trauma patients[J].Clin Transl Sci,2015,8(1):43-47.
[7] HOLCOMB J B,JENKINS D,RHEE P,et al.Damage control resuscitation:directly addressing the early coagulopathy of trauma[J].J Trauma,2007,62(2):307-310.
[8] STEVENS W T,MORSE B C,BERNARD A,et al.Incompatible type A plasma transfusion in patients requiring massive transfusion protocol:outcomes of an Eastern Association for the Surgery of Trauma multicenter study[J].J Trauma Acute Care Surg,2017,83(1):25-29.
[9] ZIELINSKI M D,JOHNSON P M,JENKINS D,et al.Emergency use of prethawed Group A plasma in trauma patients[J].J Trauma Acute Care Surg,2013,74(1):69-74;discussion 74-75.
[10] CHHIBBER V,GREENE M,VAUTHRIN M,et al.Is group A thawed plasma suitable as the first option for emergency release transfusion? (CME)[J].Transfusion,2014,54(7):1751-1755;quiz 1750.
[11] SEHEULT J N,BAHR M,ANTO V,et al.Safety profile of uncrossmatched,cold-stored,low-titer,group O+ whole blood in civilian trauma patients[J].Transfusion,2018,58(10):2280-2288.
[12] SILETZ A E,BLAIR K J,COOPER R J,et al.A pilot study of stored low titer group O whole blood + component therapy versus component therapy only for civilian trauma patients[J].J Trauma Acute Care Surg,2021,91(4):655-662.
[13] TROUGHTON M,YOUNG P P.Conservation of Rh negative Low Titer O Whole Blood (LTOWB) and the need for a national conversation to define its use in trauma transfusion protocols[J].Transfusion,2021,61(6):1966-1971.
[14] YAZER M H,CAP A P,SPINELLA P C.Raising the standards on whole blood[J].J Trauma Acute Care Surg,2018,84(6S Suppl 1):S14-S17.
[15] DUNBAR N M,KATUS M C,FREEMAN C M,et al.Easier said than done:ABO compatibility and D matching in apheresis platelet transfusions[J].Transfusion,2015,55(8):1882-1888.
[16] SOLVES P,CARPIO N,BALAGUER A,et al.Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation[J].Blood Transfus,2015,13(3):411-416.
[17] HOLCOMB J B,PATI S.Optimal trauma resuscitation with plasma as the primary resuscitative fluid:the surgeon's perspective[J].Hematology Am Soc Hematol Educ Program,2013,2013:656-659.
[18] PATI S,POTTER D R,BAIMUKANOVA G,et al.Modulating the endotheliopathy of trauma:factor concentrate versus fresh frozen plasma[J].J Trauma Acute Care Surg,2016,80(4):576-584;discussion 584-585.
[19] PENG Z L,PATI S,POTTER D,et al.Fresh frozen plasma lessens pulmonary endothelial inflammation and hyperpermeability after hemorrhagic shock and is associated with loss of syndecan 1[J].Shock,2013,40(3):195-202.
[20] SPERRY J L,GUYETTE F X,BROWN J B,et al.Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock[J].N Engl J Med,2018,379(4):315-326.
[21] DE BIASI A R,STANSBURY L G,DUTTON R P,et al.Blood product use in trauma resuscitation:plasma deficit versus plasma ratio as predictors of mortality in trauma (CME)[J].Transfusion,2011,51(9):1925-1932.
[22] DEL JUNCO D J,HOLCOMB J B,FOX E E,et al.Resuscitate early with plasma and platelets or balance blood products gradually:findings from the PROMMTT study[J].J Trauma Acute Care Surg,2013,75(1 Suppl 1):S24-S30.
[23] HOLCOMB J B,TILLEY B C,BARANIUK S,et al.Transfusion of plasma,platelets,and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma:the PROPPR randomized clinical trial[J].JAMA,2015,313(5):471-482.
[24] YAZER M,EDER A F,LAND K J.How we manage AB plasma inventory in the blood center and transfusion service[J].Transfusion,2013,53(8):1627-1633.
[25] BORGMAN M A,SPINELLA P C,PERKINS J G,et al.The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital[J].J Trauma,2007,63(4):805-813.
[26] GARRATTY G,GLYNN S A,MCENTIRE R,et al.ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States[J].Transfusion,2004,44(5):703-706.
[27] SUN Y,WANG L Q,NIU J M,et al.Distribution characteristics of ABO blood groups in China[J].Heliyon,2022,8(9):e10568.
[28] MALKIN M,NEVO A,BRUNDAGE S I,et al.Effectiveness and safety of whole blood compared to balanced blood components in resuscitation of hemorrhaging trauma patients - A systematic review[J].Injury,2021,52(2):182-188.
[29] SHEA S M,STAUDT A M,THOMAS K A,et al.The use of low-titer group O whole blood is independently associated with improved survival compared to component therapy in adults with severe traumatic hemorrhage[J].Transfusion,2020,60(Suppl 3):S2-S9.
[30] JR B A.Status of the use of universal donor blood transfusion[J].CRC Crit Rev Clin Lab Sci,1973,4(2):147-160.
[31] BARNES A.Transfusion of universal donor and uncrossmatched blood[J].Bibl Haematol,1980(46):132-142.
[32] BALLAS M,NORDSTROM E.Severe hemolysis following the transfusion of one unit of O negative blood[J].USARV Med Bull,1968,40:50-51.
[33] CROSBY W H,AKEROYD J H.Some immunohematologic results of large transfusions of group O blood in recipients of other blood groups;a study of battle casualties in Korea[J].Blood,1954,9(2):103-116.
[34] BAHR M P,YAZER M H,TRIULZI D J,et al.Whole blood for the acutely haemorrhaging civilian trauma patient:a novel idea or rediscovery?[J].Transfus Med,2016,26(6):406-414.
[35] CORDOVA C B,CAP A P,SPINELLA P C.Fresh whole blood transfusion for a combat casualty in austere combat environment[J].J Spec Oper Med,2014,14(1):9-12.
[36] SPINELLA P C,PERKINS J G,GRATHWOHL K W,et al.Fresh whole blood transfusions in coalition military,foreign national,and enemy combatant patients during Operation Iraqi Freedom at a U.S.combat support hospital[J].World J Surg,2008,32(1):2-6.
[37] YAZER M H,JACKSON B,SPERRY J L,et al.Initial safety and feasibility of cold-stored uncrossmatched whole blood transfusion in civilian trauma patients[J].J Trauma Acute Care Surg,2016,81(1):21-26.
[38] HENRICHS K F,HOWK N,MASEL D S,et al.Providing ABO-identical platelets and cryoprecipitate to (almost) all patients:approach,logistics,and associated decreases in transfusion reaction and red blood cell alloimmunization incidence[J].Transfusion,2012,52(3):635-640.
[39] 傅启华,王静.紧急抢救时ABO血型不相同血小板输注专家共识[J].中国输血杂志,2017,30(7):666-667.
[40] PIERSKALLA W P,ROACH C D.Optimal issuing policies for perishable inventory[J].Manag Sci,1972,18(11):603-614.
[41] 王鸿捷,郭永建.英国输血延误和美国血液紧缺监测概况与启示[J].中国输血杂志,2023,36(12):1171-1176.
[42] Food and Drug Administration Center for Biologics Evaluation and Research Document Control Center.Transfusion/Donation Fatalities:Fatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for Fiscal Year2016-2021[J/OL].[2024-02-20].https://www.fda.gov/vaccines-blood-biologics/report-problem-center-biologics-evaluation-research/transfusiondonation-fatalities.
[43] RUBY K N,HARM S K,DUNBAR N M.Risk of ABO-incompatible plasma from non-ABO-identical components[J].Transfus Med Rev,2021,35(4):118-122.
[44] MCCULLAGH J,CARDIGAN R,BRUNSKILL S J,et al.Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components - A scoping review[J].Blood Rev,2022,56:100989.
[45] BERSÉUS O,BOMAN K,NESSEN S C,et al.Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma[J].Transfusion,2013,53(Suppl 1):114S-123S.
[46] BELIN T R,YAZER M H,MELEDEO M A,et al.An evaluation of methods for producing low-titer group O whole blood to support military trauma resuscitation[J].J Trauma Acute Care Surg,2017,82(6S Suppl 1):S79-S86.
[47] YAZER M H,SPINELLA P C.An international survey on the use of low titer group O whole blood for the resuscitation of civilian trauma patients in 2020[J].Transfusion,2020,60(Suppl 3):S176-S179.
[48] 钱宝华,顾海慧,查占山.创伤紧急救治通用型红细胞输注专家共识[J].中国输血杂志,2017,30(7):668-669.
[49] 顾海慧,李津杞,葛立华,等.创伤紧急救治通用型红细胞输注的应用实施及效果评价[J].中国输血杂志,2019,32(9):893-897.
[50] 肖瑞卿,赵树铭,林武存,等.A、B、AB型全血加入O型全血37℃对血型鉴定、抗体效价及抗球蛋白试验的影响[J].第三军医大学学报,2005(18):1885-1887.
[51] 王培华. 输血技术学[M].第2版.北京:人民卫生出版社,2002.
[52] DUNBAR N M,YAZER M H,BIOMEDICAL Excellence for Safer Transfusion Collaborative.A possible new paradigm? A survey-based assessment of the use of thawed group A plasma for trauma resuscitation in the United States[J].Transfusion,2016,56(1):125-129.
[53] YAZER M H,SPINELLA P C,ANTO V,et al.Survey of group A plasma and low-titer group O whole blood use in trauma resuscitation at adult civilian level 1 trauma centers in the US[J].Transfusion,2021,61(6):1757-1763.
[54] DUNBAR N M,YAZER M H,BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSION (BEST) COLLABORATIVE AND THE STAT STUDY INVESTIGATORS.Safety of the use of group A plasma in trauma:the STAT study[J].Transfusion,2017,57(8):1879-1884.
[55] OLSEN G,PASSWATER M,HUGGINS M,et al.Evaluation of A plasma for incompatible patients[J].Transfusion,2021,61(2):375-378.
[56] EBERT R V,JR EMERSON C P.A clinical study of transfusion reactions:the hemolytic effect of group-o blood and pooled plasma containing incompatible isoagglutinins[J].J Clin Invest,1946,25(4):627-638.
[57] SEHEULT J N,TRIULZI D J,ALARCON L H,et al.Measurement of haemolysis markers following transfusion of uncrossmatched,low-titre,group O+ whole blood in civilian trauma patients:initial experience at a level 1 trauma centre[J].Transfus Med,2017,27(1):30-35.
[58] HARROLD I M,SEHEULT J N,ALARCON L H,et al.Hemolytic markers following the transfusion of uncrossmatched,cold-stored,low-titer,group O+ whole blood in civilian trauma patients[J].Transfusion,2020,60(Suppl 3):S24-S30.
[59] WILLIAMS J,MERUTKA N,MEYER D,et al.Safety profile and impact of low-titer group O whole blood for emergency use in trauma[J].J Trauma Acute Care Surg,2020,88(1):87-93.
[60] CURTIS B R,EDWARDS J T,HESSNER M J,et al.Blood group A and B antigens are strongly expressed on platelets of some individuals[J].Blood,2000,96(4):1574-1581.
[61] QUILLEN K,SHELDON S L,DANIEL-JOHNSON J A,et al.A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies[J].Transfusion,2011,51(1):92-96.
[62] MAIR B,BENSON K.Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets[J].Transfusion,1998,38(1):51-55.
[63] FUNG M K,DOWNES K A,SHULMAN I A.Transfusion of platelets containing ABO-incompatible plasma:a survey of 3156 North American laboratories[J].Arch Pathol Lab Med,2007,131(6):909-916.
[64] MOINUDDIN I A,MILLWARD P,FLETCHER C H.Acute intravascular hemolysis following an ABO non-identical platelet transfusion:a case report and literature review[J].Am J Case Rep,2019,20:1075-1079.
[65] FONTAINE M J,MILLS A M,WEISS S,et al.How we treat:risk mitigation for ABO-incompatible plasma in plateletpheresis products[J].Transfusion,2012,52(10):2081-2085.
[66] Transfusion of apheresis platelets and ABO groups[J].Vox Sang,2005,88(3):207-221.
[67] KARAFIN M S,BLAGG L,TOBIAN A A R,et al.ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions[J].Transfusion,2012,52(10):2087-2093.
[68] ACHERMANN F J,JULMY F,GILLIVER L G,et al.Soluble type A substance in fresh-frozen plasma as a function of ABO and Secretor genotypes and Lewis phenotype[J].Transfus Apher Sci,2005,32(3):255-262.
[69] HEGER A,BRANDSTÄTTER H,PRAGER B,et al.Universal pooled plasma (Uniplas(®)) does not induce complement-mediated hemolysis of human red blood cells in vitro[J].Transfus Apher Sci,2015,52(1):128-135.
[70] INABA K,BRANCO B C,RHEE P,et al.Impact of ABO-identical vs ABO-compatible nonidentical plasma transfusion in trauma patients[J].Arch Surg,2010,145(9):899-906.
[71] SHANWELL A,ANDERSSON T M,ROSTGAARD K,et al.Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma[J].Vox Sang,2009,96(4):316-323.
[72] MACLEOD J B A,LYNN M,MCKENNEY M G,et al.Early coagulopathy predicts mortality in trauma[J].J Trauma,2003,55(1):39-44.
[73] LEWIS M,SHULMAN I,HUDGINS J,et al.Essentials of emergency transfusion-The complement to stop the bleed[J].J Trauma Acute Care Surg,2019,87(2):420-429.
[74] MEYER D E,VINCENT L E,FOX E E,et al.Every minute counts:time to delivery of initial massive transfusion cooler and its impact on mortality[J].J Trauma Acute Care Surg,2017,83(1):19-24.
[75] 陈翔宇,刘红升,向强,等.创伤失血性休克中国急诊专家共识(2023)[J].临床急诊杂志,2023,24(12):609-623.
[76] KOTWAL R S,HOWARD J T,ORMAN J A,et al.The effect of a golden hour policy on the morbidity and mortality of combat casualties[J].JAMA Surg,2016,151(1):15-24.
[77] TRIULZI D J,ASSMANN S F,STRAUSS R G,et al.The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia[J].Blood,2012,119(23):5553-5562.
[78] PAVENSKI K,WARKENTIN T E,SHEN H,et al.Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients:an observational study[J].Transfusion,2010,50(7):1552-1560.

ABO不同型血浆输注的风险认知与临床实践进展

Risks of ABO Non-identical Plasma:Cognitive and Clinical Practice

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	中国输血协会临床输血管理学专业委员会. 术前深度单采自体红细胞和/或血小板储血技术应用中国专家共识[J]. 临床输血与检验, 2024, 26(2): 145-155.
[2]	刘睿宁, 汪德清. 血浆输注的现状与展望^*[J]. 临床输血与检验, 2024, 26(2): 180-186.
[3]	陈鑫, 邵小宝, 薛昌雯, 周琳, 朱培元. 丹参酮ⅡA抑制血小板与肿瘤细胞相互作用的实验研究^*[J]. 临床输血与检验, 2024, 26(2): 187-195.
[4]	谢慧晗, 邵小宝, 陈鑫, 周琳, 朱培元. 红景天苷用于单采血小板保存的研究^*[J]. 临床输血与检验, 2024, 26(2): 196-204.
[5]	薛昌雯, 邵小宝, 陈鑫, 周琳, 朱培元. 银杏内酯B抑制血小板与肿瘤细胞相互作用的实验研究^*[J]. 临床输血与检验, 2024, 26(2): 205-212.
[6]	严美玲, 朱培元. 基于网络药理学与分子对接探讨桃红四物汤对血小板活化的作用机制^*[J]. 临床输血与检验, 2024, 26(2): 213-222.
[7]	葛晓芹, 付恒, 胡官林, 曹彩霞, 杨维涛, 王振兴, 周国琼, 付竹筠, 孙婧雯, 沈有华, 燕锋, 鲍琳, 林富文, 李丽, 王泽颖, 冯兰洁, 周竞, 康美艳, 张剑, 刘保霞, 汤文隽, 郭萍莉, 李浩, 邱艳. 新冠肺炎疫情对国内25家地级市中心血站全血制备成分血的供应影响分析^*[J]. 临床输血与检验, 2024, 26(2): 244-250.
[8]	尚玮, 汪德清. 纤维蛋白原在创伤性大失血救治中的研究进展^*[J]. 临床输血与检验, 2024, 26(2): 274-281.
[9]	中国生物医学工程学会血液疗法与工程分会, 中国整形美容协会毛发医学分会, 富血小板血浆创新技术脱发治疗项目组. 自体单采富血小板血浆在脱发治疗中的临床应用专家共识^*[J]. 临床输血与检验, 2024, 26(1): 1-7.
[10]	阳雪新, 魏亚明. ABO非同型血小板输注的现状及建议^*[J]. 临床输血与检验, 2024, 26(1): 17-22.
[11]	樊凤艳, 马越云. 用PT/APTT指导血浆输注的几种特殊情况[J]. 临床输血与检验, 2024, 26(1): 23-28.
[12]	阳雪新, 袁咏梅, 吴兆勇, 苑召虎, 刘珍, 童欣欣, 陈小卫, 魏亚明. ABO次侧不相合血小板输注的有效性和安全性初步研究^*[J]. 临床输血与检验, 2024, 26(1): 42-48.
[13]	刁玉洁, 朱帮强, 闻慧琴, 王海婧, 胡艳, 程越, 卞茂红. 双重滤过血浆单采清除肾移植术前群体反应性抗体临床疗效及安全性观察[J]. 临床输血与检验, 2024, 26(1): 49-54.
[14]	任丽, 李晓莉, 肖松, 李小飞, 刘志忠. AB血浆倍比稀释在高效价自身抗体患者抗体筛查中的应用研究[J]. 临床输血与检验, 2024, 26(1): 66-71.
[15]	陈旭升, 杨永涛. 富血小板血浆凝胶在5例糖尿病患者难愈性植入物外露创面的临床应用[J]. 临床输血与检验, 2024, 26(1): 123-126.